Stopping LABA vs continuing use of LABA+ICS
Adverse events (all) · adults with asthma well controlled on LABA and ICS
Stopping LABA showed no clear difference in adverse events (all) compared with continuing use of LABA+ICS (moderate certainty).
1 finding from 1 review
- Stopping long‐acting beta₂‐agonists (LABA) for adults with asthma well controlled by LABA and inhaled corticosteroids 2015 · Cochrane Headline outcomes onlyOR 0.83 [0.66, 1.05]5 studies · 1339 participantsModerate